In addition, ADAM17 also promotes STAT3 activation by induction of EGFR/IL-6 transduction signaling pathways, which ultimately lead to tumor progression; inhibition of the ADAM17/IL-6/STAT3 signaling axis significantly attenuated the growth of colon cancer cells (210). Here, STAT3 is linked to neoplasm.